Choosing the Right Radiopharmaceuticals for Advanced Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics affect the use of radiopharmaceuticals in metastatic castration‑resistant prostate cancer (mCRPC).

They note that factors such as disease burden, prior therapies, and bone involvement help determine which patients may benefit most from radiopharmaceutical treatment.

The conversation also highlights the need to tailor therapy sequencing and consider combination approaches, emphasizing personalized decision‑making in this advanced disease setting.